Tag: division

TGS Prediktor Delivers PowerView™ Plant SCADA for Scatec’s Grootfontein Solar Power Project, South Africa.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and...

- Purpose Investments has filed, and been receipted for, an amendment to the Purpose Yield Shares prospectus qualifying Purpose SpaceX Yield Shares ETF.

Truth Is Everything: 72% of People Say It's More Important than Ever to Prioritize TruthResearch from McCann and Economist Enterprise reveals global growth will be driven by brands' ability to eliminate doubt and connect with the...

Priority Partners received the Impact of Excellence Award from Living Word Seventh-Day Adventist Church in honor of its work to improve community health

Artists Including Spoon, Gary Clark Jr., Ziggy Marley, STS9, Mike Campbell & The Dirty Knobs, De La Soul, Broken Social Scene, JJ Grey &...

Alert: Claims Focus on AeroVironment's Reliance on a Single-Vendor Bespoke Contract That Allegedly Left Investors Exposed When the Space Force Shifted to Multi-Vendor Commercial...

HEC Life+ flagship store marks a major milestone in the company's global expansion and commitment to science-backed wellness innovationSINGAPORE, June 11, 2026 /PRNewswire/ --...

BEIJING, June 11, 2026 /PRNewswire/ -- A report from People's Daily: The second World Conference of Classics convened on June 9 and 10 in Athens,...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Establishes a regulatory-compliant, state-of-the-art Genome-Edited (GE) Crop Field Testing Facility to accelerate global commercialization.Enables comprehensive field evaluation of a diversified crop portfolio, including drought...

IRONDALE, Ala., June 10, 2026 /PRNewswire/ -- EWTN Global Catholic Network announced today the acquisition of a majority stake in Holy Habits, a Catholic...

PHOENIX and SALT LAKE CITY, June 10, 2026 /PRNewswire/ -- Universal Technical Institute (UTI), the automotive/diesel, skilled trades, electrical and energy education division of...